Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) has received a consensus rating of “Hold” from the eight research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $31.40.
PAHC has been the topic of several research analyst reports. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. increased their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th.
View Our Latest Stock Analysis on PAHC
Insider Activity at Phibro Animal Health
Institutional Investors Weigh In On Phibro Animal Health
Several hedge funds have recently bought and sold shares of the business. Capricorn Fund Managers Ltd purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $10,233,000. Kings Path Partners LLC lifted its stake in shares of Phibro Animal Health by 87.3% in the second quarter. Kings Path Partners LLC now owns 20,600 shares of the company’s stock worth $526,000 after buying an additional 9,600 shares in the last quarter. Voya Investment Management LLC grew its holdings in shares of Phibro Animal Health by 44.3% during the first quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock valued at $681,000 after buying an additional 9,796 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $8,931,000. Finally, Trexquant Investment LP purchased a new position in Phibro Animal Health in the 1st quarter worth approximately $385,000. Institutional investors own 99.34% of the company’s stock.
Phibro Animal Health Price Performance
Shares of Phibro Animal Health stock opened at $39.72 on Friday. The business has a 50 day moving average of $40.89 and a 200 day moving average of $36.40. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $46.42. The company has a market cap of $1.61 billion, a PE ratio of 23.93, a P/E/G ratio of 1.12 and a beta of 0.79. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32.
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The business had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, equities research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current year.
Phibro Animal Health Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were issued a $0.12 dividend. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio is 28.92%.
About Phibro Animal Health
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Read More
- Five stocks we like better than Phibro Animal Health
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- This stock gets a 94 out of 100
- First Time Since 2007: All Warnings Active
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
